EPTIS
BAM Logo

Virus Genome Detection – HIV-1 Drug Resistance Determination – Standard Program for Protease and Reverse Transcriptase Inhibitors

[Virusgenom-Nachweis – HIV-1 Resistenzbestimmung – Standardprogramm für Protease- und Reverse-Transkriptase-Inhibitoren]

EPTIS factsheet 437279 | Last revision 2019-03-12 | URL: https://www.eptis.bam.de/pts437279 https://www.eptis.bam.de/pts437279

PT provider
PT provider INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
Based in Germany
Language(s) German, English
Remarks Please note: The samples can contain plasmids and heat-inactivated cell culture supernatant viruses respectively! The INSTAND EQA schemes in virology are carried out in scientific cooperation with the Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV e.V.), Gesellschaft für Virologie (GfV e.V.) and Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM e.V.). The characterization of the EQA samples including the determination of the target values/consensus values is carried out in cooperation with the INSTAND Expert laboratories. Cooperation with: Nationales Referenzzentrum für Retroviren, Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, München; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin Information for 2019 (for details please see www.instand-ev.de -> EQAS and EQAS Online)
Keywords
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Buffer and plasma, respectively (non-lyophilised) Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of protease inhibitors and reverse transcriptase inhibitors -
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants < 50
Accredited or otherwise reviewed by a 3rd party

Accredited by DAkkS (Germany) on the basis of ISO/IEC 17043

Operation is commissioned / requested by German Bundesärztekammer (General medical Council)
Fees and frequency
Participation fee 595 Euro / Survey
Regularly operated Yes (1 time per year)
Year of first operation Experience with operation of ILCs since 1968
Contact details of the PT provider
Provider Contact person
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
P.O.Box 250211, Ubierstrasse 20
40223 Düsseldorf
Germany

Phone: +49-211-159213-0
Fax: +49-211-159213-30
Web: http://www.instandev.de/ http://www.instandev.de/
Dr. rer. nat. Nathalie Wojtalewicz
Phone: +49-211-15921341
Fax: +49-211-15921330
Email: wojtalewicz@instand-ev.de wojtalewicz@instand-ev.de
If you find any mistakes please contact the responsible EPTIS coordinator in Germany, Mr Johannes van de Kreeke. Mr Johannes van de Kreeke.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5